To this end, we have previously shown a similar synergistic effect with co-exposures to Tazemetostat (an EZH2 inhibitor) and SFN in A375 melanoma cells, thus further supporting SFN’s anticancer potential in combinatorial treatment protocols with various epi-drugs (e.g., Zebularine and Tazemetostat) [43]. The gene discussed is EZH2; the disease is melanoma.